NFKB1 and glioblastoma: Mesenchymal GBM is typically characterized by a more aggressive phenotype, with enhanced invasiveness and resistance to therapy, partly driven by the activation of signalling pathways such as NF-κB, STAT3, and MAPK/ERK [86].